Thrombospondin-1: a physiological regulator of nitric oxide signaling

被引:102
作者
Isenberg, J. S. [1 ]
Frazier, W. A. [2 ]
Roberts, D. D. [1 ]
机构
[1] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA
关键词
ischemic injury; tissue perfusion; angiogenesis; hemostasis; blood flow; nitric oxide; vascular smooth muscle; platelets;
D O I
10.1007/s00018-007-7488-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thrombospondin-1 is a secreted protein that modulates vascular cell behavior via several cell surface receptors. In vitro, nanomolar concentrations of thrombospondin-1 are required to alter endothelial and vascular smooth muscle cell adhesion, proliferation, motility, and survival. Yet, much lower levels of thrombospondin-1 are clearly functional in vivo. This discrepancy was explained with the discovery that the potency of thrombospondin-1 increases more than 100-fold in the presence of physiological levels of nitric oxide (NO). Thrombospondin-1 binding to CD47 inhibits NO signaling by preventing cGMP synthesis and activation of its target cGMP-dependent protein kinase. This potent antagonism of NO signaling allows thrombospondin-1 to acutely constrict blood vessels, accelerate platelet aggregation, and if sustained, inhibit angiogenic responses. Acute antagonism of NO signaling by thrombospondin-1 is important for hemostasis but becomes detrimental for tissue survival of ischemic injuries. New therapeutic approaches targeting thrombospondin-1 or CD47 can improve recovery from ischemic injuries and overcome a deficit in NO-responsiveness in aging.
引用
收藏
页码:728 / 742
页数:15
相关论文
共 142 条
[1]   Thrombospondin 2 levels are increased in aged mice:: consequences for cutaneous wound healing and angiogenesis [J].
Agah, A ;
Kyriakides, TR ;
Letrondo, N ;
Björkblom, B ;
Bornstein, P .
MATRIX BIOLOGY, 2004, 22 (07) :539-547
[2]   The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice [J].
Agah, A ;
Kyriakides, TR ;
Lawler, J ;
Bornstein, P .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03) :831-839
[3]   Classification and pathophysiology of skin grafts [J].
Andreassi, A ;
Bilenchi, R ;
Biagioli, M ;
D'Aniello, C .
CLINICS IN DERMATOLOGY, 2005, 23 (04) :332-337
[4]   The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function [J].
Aszódi, A ;
Pfeifer, A ;
Ahmad, M ;
Glauner, M ;
Zhou, XH ;
Ny, L ;
Andersson, KE ;
Kehrel, B ;
Offermanns, S ;
Fässler, R .
EMBO JOURNAL, 1999, 18 (01) :37-48
[5]   Effect of sildenafil citrate on viability of flaps:: An experimental study in rats [J].
Ayyildiz, A ;
Uysal, A ;
Koçer, U ;
Karaaslan, Ö ;
Hrui, E ;
Germiyanoglu, C ;
Çaydere, M .
SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND SURGERY, 2005, 39 (04) :204-208
[6]   Defects in activation of nitric oxide synthases occur during delayed angiogenesis in aging [J].
Bach, MHM ;
Sadoun, E ;
Reed, MJ .
MECHANISMS OF AGEING AND DEVELOPMENT, 2005, 126 (04) :467-473
[7]   THROMBIN-SENSITIVE PROTEIN OF HUMAN PLATELET MEMBRANES [J].
BAENZIGE.NL ;
BRODIE, GN ;
MAJERUS, PW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1971, 68 (01) :240-+
[8]   SPECIFIC-INHIBITION OF ENDOTHELIAL-CELL PROLIFERATION BY THROMBOSPONDIN [J].
BAGAVANDOSS, P ;
WILKS, JW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 170 (02) :867-872
[9]  
BENEZRA D, 1993, INVEST OPHTH VIS SCI, V34, P3601
[10]   A novel enzyme immunoassay for plasma thrombospondin:: Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo [J].
Bergseth, G ;
Lappegård, KT ;
Videm, V ;
Mollnes, TE .
THROMBOSIS RESEARCH, 2000, 99 (01) :41-50